, and Lene Ryom a Purpose of review To review the evidence linking use of HIV protease inhibitors with excess risk of cardiovascular disease (CVD) in HIVþ populations.
INTRODUCTION
Recent guidelines indicate that antiretroviral therapy (ART) should be offered to all HIVþ persons irrespective of the stage of the infection. The benefits to the individual in early stages of disease comprise a reduced risk of opportunistic infections, invasive bacterial infections, tuberculosis and cancer [1, 2] . In addition, the risk of onward HIV transmission via sex, placental or infected needles is virtually nil in persons with suppressed HIV viraemia [3, 4] . Because of marked viral diversity within the body soon after initial infection, the probability of genetic variants rendering the virus less susceptible for a given antiretroviral drug is high. This can be overcome with combining agents, ensuring a genetic barrier of at least three and preferable four active antiretrovirals [5 && ]. Protease inhibitors provide a high genetic barrier and were among the first developed in the second wave of antiretroviral drug discovery in [1994] [1995] [1996] [1997] . Of the first-generation protease inhibitors, indinavir and saquinavir were the two most frequently used. Pill burden in HIVþ persons was reduced and pharmacokinetics significantly improved by blocking the P450 enzyme system with ritonavir (/r) [6, 7] . Lopinavir/r was introduced 6 years later and was preferred because of better tolerability [7, 8] . Atazanavir/r and darunavir/r were subsequently introduced and remain the favoured protease inhibitors as part of a contemporary ART regimen [9, 10] . Atazanavir/r may lead to unharmful but cosmetically unacceptable icterus in a few individuals. Darunavir/r causes gastrointestinal symptoms, but more rarely than seen in those treated with lopinavir/r [11 It remains uncertain whether ART reduces the risk of cardiovascular disease (CVD). Data from the randomized controlled trial SMART [13] , assessing continued versus intermittent use of ART, suggested that the risk may be lower for those using ART continuously, although this effect was of borderline significance (P ¼ 0.05) [14] . Conversely, cohort studies performed among persons using the first-generation ARVs as part of ART suggested a cumulative effect, with risk increasing linearly as duration of ART increased ( Fig. 1 [15, 16] ). Of note, in the first article describing this finding in observational data, (Fig. 1) , the risk of CVD in those not yet having started ART was the lowest, indicating that most of the CVD events seen in HIVþ populations were associated with the use of ART and not untreated HIV. Subsequent research until 2007-2010 indicated that this adverse effect was mainly associated with the use of the protease inhibitors available at that time [16] [17] [18] [19] . Each of the protease inhibitors used was associated with a gradually increasing CVD risk, so that the risk was not simply confined to those ever exposed, but increased as exposure increased, leading to around a 50% increase in CVD incidence after 5 years of exposure.
The range of the relative increased risk over 5 years of exposure in these studies was between 50 and 100%. Of note, the observational cohorts from where the data were derived from have been progressively more extensively treated with antidyslipidemic drugs over calendar time. This may at least in part be reflective of a reaction to the early reporting of excessive CVD risk by the responsible clinicians. Regardless, and if assuming that part of the mechanism from using protease inhibitors is how they adversely affect lipid metabolism (see section below), this more aggressive approach to managing dyslipidaemia may likely have counteracted some of the risk associated with using protease inhibitors. In support of this, the association was more pronounced in the earliest of the studies [15] than in subsequent reporting [16] [17] [18] [19] .
Population-based studies comparing the risk of CVD in HIVþ versus HIV-populations also suggest a persistent elevated risk of CVD associated with HIV status [20] [21] [22] [23] [24] . It is intriguing that adjustment for traditional CVD risk factors such as hypertension, smoking, dyslipidaemia and diabetes does not remove the CVD association with HIV status, suggesting that a higher prevalence of such traditional risk factors in the HIVþ population does not explain this finding. Recently, Klein et al. [24] published data suggesting some attenuation of the excess CVD risk over calendar time. This attenuation was potentially related to switches in approach to treat HIV using more CVD friendly drugs and being progressively more aggressive in treating traditional CVD risk factors over time.
It is possible that the excess risk of CVD from using ART may have underestimated the beneficial effects of ART on the risk of CVD in the SMART study [14] referred to above. SMART was conducted during the era when antiretrovirals associated with an increased CVD risk were more widely used, and had that not been the case, it is plausible that the group randomized to continued use of ART may have had even lower rates of CVD. Importantly, given the design of the SMART trial and the focus on persons who had been on ART for several years,
KEY POINTS
CVD remains highly prevalent in people living with HIV with a multifactorial underlying disease.
Cumulative use of certain first-generation protease inhibitors and the more recently introduced protease inhibitor darunavir has been associated with increased risk of CVD in some observational studies Dyslipidaemia and alterations of lipid metabolism may mediate the association between older first-generation protease inhibitors and CVD, whereas there is currently no known mechanism linking darunavir and CVD.
Individualized care based on underlying cardiovascular risk factors among persons treated with antiretrovirals is advisable in clinical practise. there was a sizable group of relatively older persons in the trial who were at higher risk of CVD. In the randomized START trial, performed between 2010 and 2015 [2] , there were no signs that timing of initiation of ART (immediately versus deferred) affected arterial elasticity (a proxy for atherosclerosis) [ 25 && ]. The number of CVD events was, however, too few to assess the impact of ART or type of ART directly. The trial focused on contemporary persons initiating ART, individuals were relatively young in CVD terms and the primary objective was to assess whether all persons should be offered access to ART irrespective of the stage of their infection. There was strong evidence that offering ART to all was of clinical benefit. Given these results, the question of whether ART benefits persons in terms of their CVD risk or not has become less important. Conversely, the central question in relation to HIV care moving forward, and as the HIV population is ageing and HIV is becoming a chronic disease associated with morbidity, is whether contemporarily used protease inhibitors accelerate CVD or not.
Analysis of pooled data from 19 Janssen-sponsored clinical trials did not indicate an increased risk of CVD events with darunavir/r use over treatment durations of up to 6 years, but the study was limited to 5721 persons followed for a median duration of approximately 2 years [26
&& ] recently presented data from one large observational study which for the first time indicated that darunavir/r was associated with a gradually increasing risk of CVD over 5 years of exposure similar to the earlier developed protease inhibitors. In contrast, atazanavir/r was not associated with CVD. This finding suggests, for the first time, that protease inhibitors as a class are not associated with excess risk of CVD. The key question derived from this study is whether darunavir/r indeed has a CVD risk profile comparable to that seen for first-generation and second-generation protease inhibitors and furthermore, why atazanavir/r is not associated with what otherwise appears to be class effect on CVD risk?
To address this, it is important to critically evaluate the evidence that supports a causal link between the use of protease inhibitors and increased risk of CVD.
Quality of evidence linking protease inhibitors to cardiovascular disease
No adequately powered randomized trial has yet been conducted to assess the causative relationship between contemporary protease inhibitors and CVD. Pivotal trials in HIV drug discovery are all powered to assess viral efficacy, and the sample size to establish this is sizably lower than required for studying clinical endpoints. The SMART [13] and START [2] trials, addressing strategic questions for whether to use ART continuously or not or to initiate ART in early HIV stages or not, were also not designed to directly address this.
As such, it is data derived from careful analysis of adequately powered cohort studies, with their intrinsic limitations to establish causation, which are required to provide evidence to support the causal link. Clearly, there are many limitations and bias associated with cohort studies, including most notably when assessing associations with antiretrovirals, the potential for confounding by indication. This arises when the decision to treat a specific individual with a given cART regimen is associated with the outcome. For example, a person at perceived high risk of CVD, according to his/her physician, would be treated with a different ART regimen to one not thought to be at high risk of CVD. Even with a wide range of information on potential confounding variables to adjust for, this bias may still play a role. Nonetheless, attributes from these cohort study results with the specificity to darunavir/r, but not atazanavir/r and the biological gradient render it plausible that the detected association may be causal. No study to date has been adequately powered to investigate if the observed association between darunavir/r and CVD declines when individuals are switched off darunavir/r, but if this proves to be the case it will be an important additional evidence to support causality of the association.
The association between protease inhibitors and CVD is reproducible and seen consistently in a number of cohorts and when assessing different scenarios [15] [16] [17] [18] [19] . This to some extent reducesalbeit does not remove -the risk that unknown or unmeasured confounders that could not be adjusted for might explain the association. Further, the association is characterized as a gradual increase, suggesting a dose-response effect and a slowly increasing risk as cumulative exposure increases (Fig. 1) ; a similar shape of the association was also seen for the darunavir/r signal [27 && ]. If causal, this implies that protease inhibitors gradually worsen the underlying arterial disease. There are at least two plausible mechanisms by which this may occur.
Protease inhibitors perturb lipid metabolism and lead to a proatherogenic state. This effect is demonstrated in multiple randomized controlled trials [6] [7] [8] [9] [10] 11 & ,12]. ] also demonstrated this effect in relation to darunavir/r when compared to a drug (dolutegravir) from the integrase inhibitor drug class which is known not to affect lipid metabolism. Of note, adjustment for cholesterol levels after starting protease inhibitors in observational studies attenuates (but does not remove) the association between protease inhibitor exposure and CVD risk [17, 19] . This attenuation of the association, however, was not seen for the darunavir/r signal [27 && ]. This body of evidence would suggest that although protease inhibitors perturb lipid metabolism, and that this perturbation may partly be responsible for the association between excess risk of CVD for some protease inhibitors, the potential for lipid perturbation may not be the same for all protease inhibitors and therefore is not a consistent plausible biological explanation. The other plausible explanation was observed in 2003 [29] . Protease inhibitors upregulate the accumulation of cholesteryl esters in macrophages via induction of CD36; an effect that oestrogen attenuates [30] . Macrophages of course are central in the formation of atherosclerotic plaques. Protease inhibitors might further inhibit apoptosis, which could potentially alter the turnover of plaque macrophages. Although the role of plaque apoptosis is debated and enhanced apoptosis in certain cells might alter plaque stability, inhibition may also lead to retention of harmful macrophage phenotypes [31] .
Atazanavir/r shares the two mechanisms outlined above with darunavir/r, yet the D:A:D study could not find any evidence of an increased risk of CVD associated with atazanavir/r [27 && ]. It has been proposed that the elevation of bilirubin caused by atazanavir/r may reduce any association between atazanavir/r and increased CVD risk [32, 33, 34 && ]. Marconi et al. [35] reported that higher bilirubin levels were associated with lower risk of CVD independent of other confounders.
It is questionable whether any sufficiently powered randomized clinical trial will ever be conducted to confirm the causal relationship between darunavir/r and other protease inhibitors and excess risk of CVD. This continued uncertainty needs to be incorporated into clinical management of HIVþ persons and considered alongside the other risks and benefits associated with ART. It would seem reasonable to approach the association between darunavir/r and CVD risk conservatively, taking into account both relative versus absolute risk as well as benefits and risks of ART.
RELATIVE VERSUS ABSOLUTE RISK
The key study findings reporting an association between protease inhibitors and CVD express their result in relative terms. That is, the risk of CVD was increased by, for example, 50-100% after 5 years of use. However, if the person's underlying risk of CVD is very low, a 50-100% increase in risk is minimal and the person will remain at a low risk of CVD whether or not he/she is exposed to protease inhibitors. The opposite is true if the underlying risk is high. There are now reliable and validated risk algorithms able to estimate the underlying risk [34 && ]. These risk algorithms are critical to use as part of daily practise to be able to individualize care. Not only are they able to differentiate the risk of contracting adverse drug reactions, such as CVD, but they also focus attention on the factors in the algorithms that influence the underlying risk including those being potentially modifiable and including other types of antiretroviral drugs [36] . 
BALANCING BENEFITS AND HARMS
The overall philosophy of practising medicine is to provide care for the individual to optimize the chance of benefit by weighing and potentially reducing the risk for causing harm. Quantification of risk and harm, as outlined in the above section, is hence critically important to perform. Also, the benefits of using ART (as opposed to not doing so) weigh very heavily in favour of using ART; the introduction of combination ART has led to a 90% reduction in morbidity and mortality associated with HIV [37] . For protease inhibitors, given the high genetic barrier for drugs in this class (in particular darunavir/r), these drugs are an important component of the accessible antiretroviral drugs in situations where patients have already acquired drug resistance or in situations where the risk of variable adherence (and hence acquisition of drug resistance) is high.
CONCLUSION
Protease inhibitors remain an integral part of ART, in particular because of their ability to maintain full control of viral replication in persons harbouring HIV resistant to several other of the available antiretroviral drugs. A small increased risk of CVD, which increases with increased length of exposure, may be an adverse effect from using most drugs from within this drug class, other than atazanavir/r. The evidence basis for this association is based largely on analyses from observational studies with their inherited limitations and inability to establish causality. It is plausible that the effect is driven by perturbation of cholesterol metabolism. Additional research, including adequately powered randomized trials, is required to further substantiate the evidence base for using this important drug class used as part of ART. A late-breaker presentation assessing the association between the duration of exposure of two protease inhibitors (darunavir and atazanavir -both ritonavir boosted) and CVD risk; a significant association was found with the former but not with the latter protease inhibitor. 28.
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